May 21bet365freespins, Cinda Biotech announced that its new drug marketing application (NDA) for tetumab injection has been accepted by China CDE for the treatment of Thyroid Eye Disease (TED). Tetumab (R & D codebet365freespins: IBI311) is a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody. It is reported that tetumab is the first IGF-1R antibody to be applied for marketing in China, and is expected to fill the gap in the domestic TED treatment field where no new drugs are available for 60 years.
